Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-22T07:44:09.775Z Has data issue: false hasContentIssue false
  • English
  • Français

Switching and Combining Antipsychotics

Published online by Cambridge University Press:  07 November 2014

Christoph U. Correll
Get access Rights & Permissions [Opens in a new window]

Extract

Pharmacologic knowledge can inform clinical decision-making, particularly the dosing and switching decisions made with antipsychotics. Of relevance are the pharmacokinetic (what does the body do to the drug) and the pharmacodynamic (what does the drug do to the body) properties of antipsychotics.

The goal of antipsychotic dosing is to achieve sufficient dopa-mine blockade in areas where dopamine excess can lead to psychosis, mania, or aggression. Using positron emission topography, one investigation showed that response rates were considerably higher in patients who achieved >65% striatal dopamine blockade. Conversely, striatal dopamine blockade >80% predicted the emergence of extrapyramidal symptoms (EPS) or akathisia.

There is, however, considerable intra-individual variability in achieving the desired 60% to 80% striatal dopamine blockade. Such variability is likely due to inter-individual differences in the absorption, distribution, metabolism and elimination of medications. At the same time, antipsychotics themselves differ in their general pharmacokinetic profiles. For example, ziprasidone absorption is ~50% less when ingested on an empty stomach than when taken with a meal; the degree of absorption depends on the caloric content, while the fat content is not relevant.

Type
Research Article
Information
CNS Spectrums , Volume 15 , supplement S6: Practical Dosing Strategies in the Treatment of Schizophrenia , April 2010 , pp. 8 - 11
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kapur, S, Zipursky, R, Jones, C, Remington, G, Houle, S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514–520.CrossRefGoogle ScholarPubMed
2.Frankle, WG, Gil, R, Hackett, E, et al.Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl). 2004;175(4):473–480.Google ScholarPubMed
3.Gandelman, K, Alderman, JA, Glue, Ret al.The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry. 2009;70(1):58–62.CrossRefGoogle ScholarPubMed
4.Preskorn, SH, Flockhart, D. 2006 Guide to Psychiatric Drug Interactions. Primary Psychiatry. 2006;13(4):35–64.Google Scholar
5.Flockhart, DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). http://medicine.iupui.edu/clinpharm/ddis/table.asp. Accessed January 26,2010.Google Scholar
6.Davis, JM, Chen, N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24(2):192–208.CrossRefGoogle ScholarPubMed
7.Correll, CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. JAm Acad Child Adolesc Psychiatry. 2008;47(1):9–20.CrossRefGoogle ScholarPubMed
8.Correll, CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69 Suppl 4:26–36.Google ScholarPubMed
9.Remington, G, Chue, P, Stip, E, Kopala, L, Girard, T, Christensen, B. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res. 2005;76(2–3):267–272.CrossRefGoogle ScholarPubMed
10.Ganguli, R, Brar, JS, Mahmoud, R, Berry, SA, Pandina, GJ. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med. 2008;6:17.CrossRefGoogle ScholarPubMed
11.Ryckmans, V, Kahn, JP, Modell, S, et al.Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry. 2009:42(3):114–121.CrossRefGoogle ScholarPubMed
12.Correll, CU. Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment? J Clin Psychiatry. 2008;69(4):674–675.CrossRefGoogle ScholarPubMed
13.Miller, AL, Hall, CS, Buchanan, RW, et al.The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65(4):500–508.CrossRefGoogle ScholarPubMed
14.Lehman, AF, Lieberman, JA, Dixon, LB, et al.Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004:161(2 Suppl):1–56.Google ScholarPubMed
15.Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443–457.CrossRefGoogle ScholarPubMed
16.Leucht, S, Kissling, W, McGrath, J. Lithium for schizophrenia. Cochrane Database Syst Rev. 2007(3):CD003834.Google Scholar
17.Leucht, S, Kissling, W, McGrath, J, White, P. Carbamazepine for schizophrenia. Cochrane Database Syst Rev. 2007(3):CD001258.Google Scholar
18.Cheine, M, Ahonen, J, Wahlbeck, K. Beta-blocker supplementation of standard drug treatment for schizophrenia. Cochrane Database Syst Rev. 2001(3):CD000234.Google Scholar
19.Volz, A, Khorsand, V, Gillies, D, Leucht, S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2007(1):CD006391.Google Scholar
20.Schwarz, C, Volz, A, Li, C, Leucht, S. Valproate for schizophrenia. Cochrane Database Syst Rev. 2008(3):CD004028.Google Scholar
21.Goff, DC, Keefe, R, Citrome, L, et al.Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol. 2007:27(6):582–589.CrossRefGoogle ScholarPubMed
22.Tiihonen, J, Wahlbeck, K, Kiviniemi, V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009;109(1–3):10–14.CrossRefGoogle ScholarPubMed
23.Tharyan, P, Adams, CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. 2005(2):CD000076.Google Scholar
24.Rummel, C, Kissling, W, Leucht, S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res. 2005:80(1):85–97.CrossRefGoogle ScholarPubMed
25.Whitehead, C, Moss, S, Cardno, A, Lewis, G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med. 2003;33(4):589–599.CrossRefGoogle ScholarPubMed
26.Correll, CU. Real-life dosing with second-generation antipsychotics. J Clin Psychiatry. 2005;66(12):1610–1611.CrossRefGoogle ScholarPubMed